Mineralys Therapeutics, Inc.

NasdaqGS MLYS

Mineralys Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -2.96

Mineralys Therapeutics, Inc. Price to Earnings Ratio (P/E) is -2.96 on January 14, 2025, a 39.13% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Mineralys Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.96 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
  • Mineralys Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.05 on February 26, 2024, which is -205.64% below the current Price to Earnings Ratio (P/E).
  • Mineralys Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -5.43.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
NasdaqGS: MLYS

Mineralys Therapeutics, Inc.

CEO Mr. Jon Congleton
IPO Date Feb. 10, 2023
Location United States
Headquarters 150 N. Radnor Chester Rd.
Employees 28
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

StockViz Staff

January 15, 2025

Any question? Send us an email